Skip to main content
KOMIPHARM INTERNATIONAL CO., LTD. logo

KOMIPHARM INTERNATIONAL CO., LTD. — Investor Relations & Filings

Ticker · 041960 ISIN · KR7041960006 KO Manufacturing
Open in API
Filings indexed 326 across all filing types
Latest filing 2020-03-10 AGM Information
Country KR South Korea
Listing KO 041960

About KOMIPHARM INTERNATIONAL CO., LTD.

https://komipharm.co.kr/en/

Komipharm International Co., Ltd. is a biopharmaceutical company engaged in the development, manufacturing, and sale of products for both animal and human health. Its Animal Health Division provides a portfolio of veterinary vaccines, pharmaceuticals, and disinfectants. The company's Pharmaceutical Division is dedicated to the research and development of novel therapeutic agents, with key research areas including anticancer drugs and treatments for cancer-related pain and autoimmune diseases. Leveraging extensive experience, the company focuses on intensive R&D to expand its presence in the global bio-industry.

Recent filings

Filing Released Lang Actions
주주총회집중일개최사유신고
AGM Information Classification · 98% confidence The document is a formal regulatory filing submitted to the KRX (Korea Exchange) regarding the 'Reason for Holding a General Meeting of Shareholders on a Concentrated Date'. It explains the scheduling constraints for the company's Annual General Meeting (AGM) due to financial reporting requirements. Since it is a regulatory announcement regarding the logistics of a shareholder meeting rather than the meeting materials themselves or a proxy statement, it falls under the general regulatory filing category.
2020-03-10 Korean
주주총회소집결의
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) issued by Kormipharm. It outlines the date, location, and agenda items (such as financial statement approval, stock option grants, and director remuneration). This document serves as the official proxy solicitation and information statement provided to shareholders to inform them of the upcoming meeting and the matters to be voted upon.
2020-03-06 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 95% confidence The document is a regulatory filing from a Korean company (KomiPharm) announcing a significant change in financial results (revenue or profit/loss structure exceeding 15% for large corporations or 30% for others). It provides a comparative table of financial data (revenue, operating profit, net income) between the current and previous fiscal years, along with the reasons for the change. This type of disclosure is a standard regulatory requirement for listed companies to inform the market of material financial shifts before the final audit is completed. It fits the 'Earnings Release' (ER) category as it provides the initial announcement of financial results and key highlights. FY 2019
2020-02-26 Korean
투자판단관련주요경영사항(당사 개발 진행 중인 신약물질 파나픽스(Panaphix)의 국내 식약처 긴급임상시험 신청)
Regulatory Filings Classification · 95% confidence The document is a regulatory filing from KOSDAQ-listed company Komipharm regarding a 'Major Management Matter' (투자판단 관련 주요경영사항). It details the company's application for an emergency clinical trial for its drug candidate 'Panaphix' to treat COVID-19 pneumonia. This is a specific regulatory disclosure of a material business event, which falls under the 'Regulatory Filings' category as it does not fit into specific categories like M&A, dividends, or financial reports.
2020-02-26 Korean
투자판단관련주요경영사항(뇌전이 비소세포 폐암환자 대상 PAX-1 치료연구 2상에 대한 대만식약청(TFDA) 임상시험계획승인)
Legal Proceedings Report Classification · 95% confidence The document is a regulatory filing from a Korean company (Komipharm) regarding a 'major management matter' (투자판단 관련 주요경영사항), specifically announcing the approval of a Phase 2 clinical trial by the Taiwan Food and Drug Administration (TFDA). This type of disclosure is a standard regulatory announcement for material corporate events in the Korean market. Since it does not fit into specific categories like financial reports, dividends, or board changes, it falls under the general regulatory filing category.
2020-02-24 Korean
단일판매ㆍ공급계약체결
Regulatory Filings Classification · 95% confidence The document is a formal regulatory filing from KOSDAQ-listed company KomiPharm regarding a 'Single Sale/Supply Contract' (단일판매ㆍ공급계약체결) with the Public Procurement Service. It details the contract value, duration, and terms. Since this is a specific regulatory disclosure of a material business event (contract signing) that does not fit into the other specialized categories like M&A or financial reports, it falls under the general regulatory filing category.
2020-01-07 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.